Hims & Hers Health (NYSE:HIMS) Shares Up 5.7% - Here's Why

Key Points

• Hims & Hers Health shares rose 5.7% during trading on Friday, with a last trade price of $58.02, despite a significant decline in trading volume compared to its average.
• Recent analyst ratings show a mix of sentiments, with a consensus rating of "Reduce" and target prices ranging from $37.00 to $68.00 for the stock.
• In insider trading, CFO Oluyemi Okupe and CEO Andrew Dudum sold significant shares, representing a 52.92% and 22.96% decrease in their holdings, respectively.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) shares were up 5.7% during trading on Friday . The stock traded as high as $58.02 and last traded at $58.02. Approximately 12,194,113 shares traded hands during trading, a decline of 63% from the average daily volume of 32,840,805 shares. The stock had previously closed at $54.87.

Analyst Ratings Changes

A number of equities research analysts have weighed in on HIMS shares. Morgan Stanley reaffirmed an "equal weight" rating and issued a $40.00 target price on shares of Hims & Hers Health in a report on Wednesday, June 11th. Truist Financial lowered their target price on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a research note on Monday, August 18th. Wall Street Zen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Canaccord Genuity Group reiterated a "buy" rating and set a $68.00 price objective on shares of Hims & Hers Health in a research report on Friday, September 12th. Finally, Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Hims & Hers Health currently has a consensus rating of "Reduce" and a consensus price target of $38.92.

Hims & Hers Health Stock Up 5.8%

The company has a market cap of $13.13 billion, a price-to-earnings ratio of 72.52, a P/E/G ratio of 3.60 and a beta of 2.14. The stock's 50-day moving average is $51.06 and its 200-day moving average is $46.19. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. During the same period last year, the firm posted $0.06 earnings per share. The company's revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 145,000 shares of the firm's stock in a transaction on Monday, September 15th. The stock was sold at an average price of $55.35, for a total transaction of $8,025,750.00. Following the transaction, the chief financial officer directly owned 128,984 shares in the company, valued at approximately $7,139,264.40. This trade represents a 52.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 660,000 shares of the stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the completion of the sale, the chief executive officer owned 2,214,769 shares of the company's stock, valued at approximately $112,023,016.02. This represents a 22.96% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,537,662 shares of company stock valued at $78,424,548. 13.71% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors have recently added to or reduced their stakes in HIMS. Smartleaf Asset Management LLC boosted its position in Hims & Hers Health by 15.7% during the 1st quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company's stock valued at $49,000 after buying an additional 227 shares during the period. Bessemer Group Inc. grew its stake in shares of Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company's stock worth $30,000 after purchasing an additional 312 shares during the last quarter. True Vision MN LLC increased its holdings in Hims & Hers Health by 3.6% during the 2nd quarter. True Vision MN LLC now owns 9,376 shares of the company's stock valued at $467,000 after purchasing an additional 328 shares during the period. Allworth Financial LP raised its position in Hims & Hers Health by 20.0% during the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company's stock valued at $56,000 after purchasing an additional 334 shares during the last quarter. Finally, Signaturefd LLC grew its position in shares of Hims & Hers Health by 17.7% in the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company's stock worth $76,000 after buying an additional 388 shares during the last quarter. Institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.